5-((1,3-Diphenyl-1H-pyrazol-4-yl)methylene)-3-octyl-2-thioxothiazolidin-4-one

Catalog No. :
ACOOBA104
CAS No. :
623940-35-2
Molecular Formula :
C27H29N3OS2
Molecular Weight :
475.68

IUPAC Name:(Z)-5-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)-3-octyl-2-thioxothiazolidin-4-one

5-((1,3-Diphenyl-1H-pyrazol-4-yl)methylene)-3-octyl-2-thioxothiazolidin-4-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name5-((1,3-Diphenyl-1H-pyrazol-4-yl)methylene)-3-octyl-2-thioxothiazolidin-4-one
IUPAC Name(Z)-5-((1,3-diphenyl-1H-pyrazol-4-yl)methylene)-3-octyl-2-thioxothiazolidin-4-one
MDL No.MFCD04441509
Molecular FormulaC27H29N3OS2
Molecular Weight475.68
SMILESO=C1N(CCCCCCCC)C(S/C1=C\C2=CN(C3=CC=CC=C3)N=C2C4=CC=CC=C4)=S
InChI KeyZPUDENWDZVXBGA-CLCOLTQESA-N
SynonymSALOR-INT L440833-1EA;(5Z)-5-[(1,3-DIPHENYL-1H-PYRAZOL-4-YL)METHYLENE]-3-OCTYL-2-THIOXO-1,3-THIAZOLIDIN-4-ONE;4-Thiazolidinone, 5-[(1,3-diphenyl-1H-pyrazol-4-yl)methylene]-3-octyl-2-thioxo-
CAS No.623940-35-2

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACOOBA104 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACCJQO567 route compound structure diagram
    ACCJQO56721487-45-6 In Stock
  4. Then
  5. ACOOBA104 route product structure diagram
    ACOOBA104623940-35-2
Inquiry

2. ACOOBA104 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOOBA104 route product structure diagram
    ACOOBA104623940-35-2
Inquiry

Comments (0)